QuidelOrtho (NASDAQ:QDEL) Stock Falls 9.2% – Time to Sell?

Posted by Stanley Muller on Nov 6th, 2026

QuidelOrtho Corporation (NASDAQ:QDEL – Get Free Report)’s stock price traded down 9.2% during trading on Friday. The company traded as low as $11.62 and last traded at $11.6590. Approximately 488,315 shares were traded during mid-day trading, a decline of 73% from the average session volume of 1,794,815 shares. The stock had previously closed at $12.84.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of QuidelOrtho in a report on Thursday, October 15th. Zacks Research raised QuidelOrtho from a “strong sell” rating to a “hold” rating in a research note on Friday, October 9th. Four analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Reduce” and an average target price of $13.62.

Get Our Latest Report on QuidelOrtho

QuidelOrtho Price Performance

The company has a quick ratio of 0.76, a current ratio of 1.36 and a debt-to-equity ratio of 1.40. The business’s 50-day simple moving average is $12.68 and its 200 day simple moving average is $16.07. The firm has a market capitalization of $772.84 million, a P/E ratio of -2.08 and a beta of 0.77.

QuidelOrtho (NASDAQ:QDEL – Get Free Report) last announced its quarterly earnings data on Tuesday, November 3rd. The company reported $0.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.18 by $0.13. QuidelOrtho had a negative net margin of 14.24% and a positive return on equity of 3.22%. The company had revenue of $618.90 million during the quarter, compared to analysts’ expectations of $627.83 million. During the same quarter in the prior year, the company earned $0.80 EPS. The firm’s revenue was down 11.6% on a year-over-year basis. Sell-side analysts forecast that QuidelOrtho Corporation will post 0.68 earnings per share for the current year.

Institutional Trading of QuidelOrtho

Institutional investors have recently added to or reduced their stakes in the business. Moody National Bank Trust Division increased its holdings in shares of QuidelOrtho by 1.1% in the second quarter. Moody National Bank Trust Division now owns 70,748 shares of the company’s stock worth $1,239,000 after buying an additional 789 shares during the period. GAMMA Investing LLC lifted its stake in shares of QuidelOrtho by 67.7% in the 2nd quarter. GAMMA Investing LLC now owns 2,185 shares of the company’s stock valued at $38,000 after acquiring an additional 882 shares during the last quarter. Bfsg LLC boosted its holdings in QuidelOrtho by 6.0% during the 3rd quarter. Bfsg LLC now owns 17,550 shares of the company’s stock valued at $185,000 after acquiring an additional 995 shares during the period. Yousif Capital Management LLC boosted its holdings in QuidelOrtho by 8.8% during the 3rd quarter. Yousif Capital Management LLC now owns 21,982 shares of the company’s stock valued at $232,000 after acquiring an additional 1,780 shares during the period. Finally, Allworth Financial LP grew its position in QuidelOrtho by 161.3% during the 2nd quarter. Allworth Financial LP now owns 3,209 shares of the company’s stock worth $56,000 after acquiring an additional 1,981 shares during the last quarter. 99.00% of the stock is currently owned by hedge funds and other institutional investors.

About QuidelOrtho

(Get Free Report)

QuidelOrtho Corporation (NASDAQ:QDEL) is a global in vitro diagnostics company formed through the combination of Quidel Corporation and Ortho Clinical Diagnostics, a transaction completed in 2022. The company develops, manufactures and markets diagnostic technologies used to detect disease, guide treatment decisions and support blood-transfusion safety.

Its portfolio includes rapid immunoassays, molecular testing systems, clinical chemistry and immunohematology products, as well as laboratory automation solutions.